| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC22206 | Cathepsin B inhibitor RC1 | Cathepsin B inhibitor RC1 is a small-molecule that blocks the process of anthrax lethal toxin (LT) cytotoxicity, inhibits enzymatic activity of host cathepsin B that mediates the escape of toxins into the cytoplasm from late endosomes. |
|
| DC12099 | CAY10595 | CAY10595 is a potent CRTH2/DP2 receptor antagonist that binds to the human receptor with a Ki of 10 nM. |
|
| DC20607 | Cazpaullone | Cazpaullone (9-Cyano-1-azapaullone) is a derivative of 1-Azakenpaullone, a potent, selective GSK3β inhibitor with IC50 of 8 nM, weakly inhibits CDK1/cyclin B and CDK5/p25 (IC50=0.5 and 0.3 uM). |
|
| DC11709 | CB-1158 | CB-1158 (INCB-01158) is a potent, selective, oral available Arginase inhibitor with IC50 of 98 nM. |
|
| DC22986 | CB5305630 | CB5305630 is a potent and noncompetitive IRE1 RNase inhibitor with IC50 of 60 nM in the FRET-derepression assay. |
|
| DC20861 | CB-618 | CB-618 (CB 238618) is a novel non-β-lactam β-lactamase inhibitor that potentiates meropenem MIC values against clinical Enterobacteriaceae isolates. |
|
| DC20862 | CB-618 sodium salt | CB-618 (CB 238618) is a novel non-β-lactam β-lactamase inhibitor that potentiates meropenem MIC values against clinical Enterobacteriaceae isolates. |
|
| DC20863 | CB-6673567 | CB-6673567 is a potent, selective Adenylyl Cyclase 1 (AC1) inhibitor with IC50 of 77 uM, displays a 2- to 4-fold isoform selectivity over AC6. |
|
| DC10944 | CBB3001 | CBB3001 (CBB-3001) is a novel potent, selective histone demethylase LSD1 inhibitor with IC50 of 21.25 uM. |
|
| DC12623 | CBK289001 | CBK289001 (CBK-289001) is a small molecule inhibitor of Tartrate-resistant acid phosphatase (TRAP/ACP5), demonstrates efficacy in a migration assay and IC50 values from 4 to 125 uM.. |
|
| DC10146 | CC-122（Avadomide） Featured | CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity.CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL. |
|
| DC20866 | CC-671 Featured | CC-671 is a potent, selective, dual TTK (Mps1)/CLK2 inhibitor with IC50 of 5/3 nM, respectively. |
|
| DC11588 | CC-885 Featured | CC-885 (CC 885, CC885) is a novel E3 ligase cereblon (CRBN) modulator with potent anti-tumour activity mediated through the degradation of GSPT1. |
|
| DC12532 | CC-90003 | CC-90003 (CC90003) is a potent and selective, covalent ERK1/2 inhibitor with IC50 of 10-20 nM, demonstrates excellent selectivity in a 258-kinase biochemical assay panel. |
|
| DC23540 | CCC07-01 | CCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays. |
|
| DC20867 | CCG 102487 | CCG 102487 is a CCG-2979 analog that reduces streptokinase (SK) activity with little inhibition of group A streptococcal (GAS) growth. |
|
| DC20871 | CCG 2979 | CCG 2979 is a small molecule inhibitor of gene expression of streptokinase (SK), a critical group A streptococcal (GAS) virulence factor. |
|
| DC10977 | CCG-222740 | CCG-222740 (CCG222740) is a pharmacological inhibitor of MRTF/SRF signalling, shows greater inhibitory effect on MRTF/SRF target genes than MRTF-A inhibitor CCG-203971, with IC50 of 5 uM in fibroblast-mediated collagen contraction assay. |
|
| DC20869 | CCG-232601 | CCG-232601 is a potent (IC50=0.55 uM), orally bioavailable Rho/MKL1/SRF transcriptional pathway that target transcriptional factor MRTF. |
|
| DC22819 | CCG-50014 Featured | CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site. CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test. |
|
| DC9612 | CCG-63802 | CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) protein; with greatest potency at RGS4. IC50 value: Target: RGS CCG-63802 is selective amongst RGS proteins, with greatest potency at RGS4. |
|
| DC9613 | CCG-63808 | CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins. |
|
| DC22050 | CCI-006 | CCI-006 (CCI 006) is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias that share common leukemogenic pathways. |
|
| DC22049 | CCI-007 | CCI-007 (CCI 007) is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485. |
|
| DC26030 | CCMI Featured | CCMI is a positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptors (nAChR). |
|
| DC12639 | CCR1 inhibitor 19e | CCR1 inhibitor 19e is a novel potent, selective CCR1 antagonist with IC50 of 6.8 nM, inhibits CCR1chemotaxis in THP-1 cells with IC50 of 28 nM.. |
|
| DC23528 | CCR10 antagonist 1 | CCR10 antagonist 1 is a potent, selective CCR10 antagonist with IC50 of 690 nM. |
|
| DC12177 | CCR2 antagonist 1 | CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM. |
|
| DC11204 | CCR6 inhibitor 35 | CCR6 inhibitor 35 is a potent and selective CCR6 inhibitor with IC50 of 6.0 nM (hCCR6). |
|
| DC20876 | CCT 068127 | CCT 068127 (CCT68127) is a novel potent inhibitor of CDK2 and CDK9 with IC50 of 10 and 90 nM for CDK2/E and CDK9/T, respectively. |
|
